Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate the superiority of secukinumab 150 mg and/or 300 mg to placebo in subjects with moderate to severe palmoplantar psoriasis as assessed by the palmoplantar Investigator's Global Assessment (ppIGA) at Week 16
Critère d'inclusion
- moderate to severe palmoplantar psoriasis